In particular, intraperitoneal injections of anti-human LTβR agonistic monoclonal antibodies every 14 days resulted in reduced tumor growth in athymic nude mice subcutaneously inoculated with WiDr human colon adenocarcinoma, whereas a single injection of the anti-mouse LTβR agonistic monoclonal antibody caused tumor necrosis in BALB/c mice with CT26 colon carcinoma [33]. Here, LTBR is linked to colon adenocarcinoma.